ABBV analyst scorecard · AbbVie
63 rating actions on ABBV in the last 12 months. Of 85 price targets that resolved, 37 were reached while they stood, 48 were replaced by the same firm first, and 0 fell short at their deadline. Ratings: 84% Buy-type, 16% Hold-type, 0% Sell-type. Consensus target $283, 2% below the last close.
Checked through 2026-10-29 · last close $289.30 (2026-10-29). Rebuilt every morning.
What the Holds say: 9 Hold-type ratings on ABBV in the last 12 months carried a median target +3% from the price on the day; 22% sat below it.
The 3 upgrades on ABBV came after an average +0.7% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Buy | 2026-08-03 | $290 | 0 | 4 | 4 | — |
| Evercore ISI Group | Outperform | 2026-08-10 | $260 | 2 | 2 | 4 | 1 of 1 |
| Piper Sandler | Overweight | 2026-08-20 | $303 | 1 | 6 | 7 | 1 of 1 |
| Morgan Stanley | Overweight | 2026-10-07 | $310 | 0 | 10 | 10 | 1 of 1 |
| Guggenheim | Buy | 2026-10-09 | $288 | 5 | 4 | 9 | 1 of 1 |
| Cantor Fitzgerald | Overweight | 2026-10-08 | $290 | 3 | 4 | 7 | 1 of 1 |
| Citigroup | Neutral | 2026-07-15 | $260 | 4 | 4 | 8 | — |
| Wolfe Research | Outperform | 2026-08-13 | $300 | 1 | 0 | 1 | 1 of 1 |
| Berenberg | Buy | 2026-08-06 | $275 | 1 | 1 | 2 | 0 of 1 |
| Erste Group | Buy | 2026-08-05 | — | — | — | 0 | — |
| TD Cowen | Buy | 2026-07-31 | $280 | 1 | 0 | 1 | — |
| William Blair | Buy | 2026-07-31 | — | — | — | 0 | — |
| BMO Capital | Outperform | 2026-07-13 | $300 | 2 | 2 | 4 | 1 of 1 |
| JPMorgan | Overweight | 2026-10-08 | $300 | 3 | 1 | 4 | 1 of 1 |
| HSBC | Buy | 2026-09-10 | $315 | 1 | 0 | 1 | — |
| Wells Fargo | Overweight | 2026-08-17 | $300 | 2 | 2 | 4 | 1 of 1 |
| UBS | Neutral | 2026-10-09 | $275 | 1 | 0 | 1 | — |
| Barclays | Overweight | 2026-10-21 | $325 | 0 | 2 | 2 | — |
| RBC Capital | Outperform | 2026-10-13 | $280 | 2 | 0 | 2 | — |
| Freedom Broker | Buy | 2026-02-17 | $260 | 1 | 1 | 2 | — |
| Goldman Sachs | Neutral | 2026-10-23 | $294 | — | — | 0 | — |
| Scotiabank | Sector Outperform | 2026-10-06 | $320 | — | — | 0 | — |
| BNP Paribas | Neutral | 2026-08-11 | $247 | — | — | 0 | — |
| Bank of America | Buy | 2026-07-10 | $276 | 3 | 2 | 5 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor ABBV carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-23 | Goldman Sachs | Neutral | maintained | $285.64 | $294 | within 5% of price when set | +7.8% |
| 2026-10-21 | Barclays | Overweight | maintained | $284.80 | $325 | running to 2027-10-21 | +7.7% |
| 2026-10-13 | RBC Capital | Outperform | reiterated | $274.36 | $280 | within 5% of price when set | +6.7% |
| 2026-10-09 | UBS | Neutral | maintained | $276.47 | $275 | within 5% of price when set | +10.2% |
| 2026-10-09 | Guggenheim | Buy | reiterated | $276.47 | $288 | within 5% of price when set | +10.2% |
| 2026-10-08 | JPMorgan | Overweight | maintained | $272.42 | $300 | running to 2027-10-08 | +9.5% |
| 2026-10-08 | Cantor Fitzgerald | Overweight | maintained | $272.42 | $290 | running to 2027-10-08 | +9.5% |
| 2026-10-07 | Morgan Stanley | Overweight | maintained | $271.36 | $310 | running to 2028-04-07 | +5.8% |
| 2026-10-06 | Scotiabank | Sector Outperform | maintained | $266.69 | $320 | running to 2027-10-06 | +4.0% |
| 2026-09-10 | HSBC | Buy | maintained | $255.00 | $315 | running to 2027-09-10 | +2.0% |
| 2026-08-20 | Piper Sandler | Overweight | maintained | $261.83 | $303 | running to 2027-08-20 | +2.2% |
| 2026-08-17 | Wells Fargo | Overweight | maintained | $250.33 | $300 | running to 2027-08-17 | -1.6% |
| 2026-08-13 | Wolfe Research | Peer Perform → Outperform | upgrade | $250.82 | $300 | running to 2027-08-13 | +2.5% |
| 2026-08-11 | BNP Paribas | Neutral | maintained | $250.09 | $247 | within 5% of price when set | +0.8% |
| 2026-08-10 | Evercore ISI Group | Outperform | maintained | $247.97 | $260 | within 5% of price when set | -0.0% |
| 2026-08-06 | Berenberg | Buy | maintained | $243.87 | $275 | reached 2026-10-09 | -4.2% |
| 2026-08-05 | Erste Group | Hold → Buy | upgrade | $246.20 | — | no target | -3.4% |
| 2026-08-04 | Guggenheim | Buy | maintained | $243.80 | $288 | reached 2026-10-20 | -6.6% |
| 2026-08-03 | Canaccord Genuity | Buy | maintained | $245.10 | $290 | running to 2027-08-03 | -6.1% |
| 2026-08-03 | Cantor Fitzgerald | Overweight | maintained | $245.10 | $285 | replaced 2026-10-08, new $290 | -6.1% |
| 2026-08-03 | Morgan Stanley | Overweight | maintained | $245.10 | $296 | replaced 2026-10-07, new $310 | -6.1% |
| 2026-07-31 | TD Cowen | Buy | maintained | $250.94 | $280 | reached 2026-10-12 | -0.1% |
| 2026-07-31 | William Blair | Buy | maintained | $250.94 | — | no target | -0.1% |
| 2026-07-29 | Barclays | Overweight | maintained | $263.30 | $300 | replaced 2026-10-21, new $325 | +3.5% |
| 2026-07-22 | Canaccord Genuity | Buy | maintained | $253.30 | $282 | replaced 2026-08-03, new $290 | +10.1% |
| 2026-07-15 | Citigroup | Neutral | maintained | $244.11 | $260 | reached 2026-07-28 | +10.2% |
| 2026-07-13 | UBS | Neutral | maintained | $248.00 | $260 | within 5% of price when set | +8.9% |
| 2026-07-13 | BMO Capital | Outperform | maintained | $248.00 | $300 | running to 2027-07-13 | +8.9% |
| 2026-07-10 | Bank of America | Buy | maintained | $248.08 | $276 | reached 2026-10-09 | +10.3% |
| 2026-07-10 | RBC Capital | Outperform | maintained | $248.08 | $280 | reached 2026-10-12 | +10.3% |
| 2026-07-10 | Wells Fargo | Overweight | maintained | $248.08 | $295 | replaced 2026-08-17, new $300 | +10.3% |
| 2026-07-09 | Guggenheim | Buy | maintained | $249.91 | $261 | within 5% of price when set | +10.9% |
| 2026-07-09 | JPMorgan | Overweight | maintained | $249.91 | $280 | replaced 2026-10-08, new $300 | +10.9% |
| 2026-07-06 | Cantor Fitzgerald | Overweight | maintained | $254.76 | $265 | within 5% of price when set | +12.1% |
| 2026-06-23 | Piper Sandler | Overweight | reiterated | $234.76 | $298 | replaced 2026-08-20, new $303 | +8.8% |
| 2026-06-23 | Canaccord Genuity | Buy | maintained | $234.76 | $273 | replaced 2026-07-22, new $282 | +8.8% |
| 2026-05-15 | Evercore ISI Group | Outperform | maintained | $210.39 | $235 | reached 2026-06-25 | +0.9% |
| 2026-05-14 | Piper Sandler | Overweight | maintained | $210.77 | $298 | replaced 2026-08-20, new $303 | +0.2% |
| 2026-05-04 | Evercore ISI Group | Outperform | maintained | $208.16 | $236 | replaced 2026-05-15, new $235 | -0.3% |
| 2026-05-01 | Guggenheim | Buy | reiterated | $206.60 | $249 | reached 2026-06-26 | -3.9% |
| 2026-04-30 | Canaccord Genuity | Buy | maintained | $211.32 | $265 | replaced 2026-06-23, new $273 | -2.8% |
| 2026-04-30 | Morgan Stanley | Overweight | maintained | $211.32 | $278 | replaced 2026-08-03, new $296 | -2.8% |
| 2026-04-30 | Cantor Fitzgerald | Overweight | reiterated | $211.32 | $240 | reached 2026-06-25 | -2.8% |
| 2026-04-23 | Piper Sandler | Overweight | maintained | $200.95 | $294 | replaced 2026-05-14, new $298 | -2.1% |
| 2026-04-21 | Canaccord Genuity | Buy | initiated | $205.12 | $262 | replaced 2026-04-30, new $265 | +0.0% |
| 2026-04-10 | Guggenheim | Buy | maintained | $207.94 | $249 | reached 2026-06-26 | -8.7% |
| 2026-04-08 | Cantor Fitzgerald | Overweight | maintained | $211.59 | $240 | reached 2026-06-25 | -7.0% |
| 2026-02-25 | RBC Capital | Outperform | initiated | $226.92 | $260 | reached 2026-07-02 | +2.8% |
| 2026-02-20 | Barclays | Overweight | initiated | $224.81 | $275 | replaced 2026-07-29, new $300 | +4.0% |
| 2026-02-18 | Piper Sandler | Overweight | maintained | $228.72 | $299 | replaced 2026-04-23, new $294 | +6.7% |
| 2026-02-17 | Freedom Broker | Buy | maintained | $232.86 | $260 | reached 2026-07-02 | +8.6% |
| 2026-02-05 | UBS | Neutral | maintained | $219.02 | $230 | reached 2026-02-13 | -2.2% |
| 2026-02-05 | Evercore ISI Group | Outperform | maintained | $219.02 | $228 | within 5% of price when set | -2.2% |
| 2026-02-05 | Morgan Stanley | Overweight | maintained | $219.02 | $270 | replaced 2026-04-30, new $278 | -2.2% |
| 2026-01-27 | Citigroup | Neutral | maintained | $223.93 | $230 | within 5% of price when set | -2.6% |
| 2026-01-08 | Wolfe Research | Outperform → Peer Perform | downgrade | $224.13 | — | no target | +0.5% |
| 2025-12-12 | Morgan Stanley | Overweight | maintained | $223.32 | $269 | replaced 2026-02-05, new $270 | -4.2% |
| 2025-12-10 | HSBC | Hold → Buy | upgrade | $225.18 | $265 | reached 2026-08-19 | +3.0% |
| 2025-11-12 | Freedom Broker | Buy | maintained | $233.23 | $245 | replaced 2026-02-17, new $260 | — |
| 2025-11-07 | UBS | Neutral | maintained | $219.16 | $220 | within 5% of price when set | — |
| 2025-11-05 | Piper Sandler | Overweight | reiterated | $216.77 | $289 | replaced 2026-02-18, new $299 | — |
| 2025-11-03 | Citigroup | Neutral | maintained | $211.96 | $235 | reached 2025-11-21 | — |
| 2025-11-03 | JPMorgan | Overweight | maintained | $211.96 | $260 | reached 2026-07-02 | — |
Also in Pharma
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.